#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neurodegenerative disorder B precursor type acute leukaemia Alport's syndrome Gastrointestinal disorder Cognitive disorder Cerebral amyloid angiopathy Activated PI3 kinase delta syndrome Restless legs syndrome Pericarditis Metastatic malignant melanoma Splenic marginal zone lymphoma Neuroblastoma Facioscapulohumeral muscular dystrophy Bronchopulmonary dysplasia Cardiac arrest More trials…

    Learn about Rare Diseases

    Hereditary hypophosphataemic rickets – Basic Information Von Willebrand’s disease – Trials in Disease Sarcoidosis Toxic epidermal necrolysis – Diagnostics Hereditary ataxia Mucopolysaccharidosis – Trials in Disease Congenital generalised lipodystrophy – Diagnostics Breast angiosarcoma – Basic Information Ewing’s sarcoma – Life with Disease Pleural mesothelioma malignant – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Acasunlimab IMEROPRUBART Entrectinib Thiamazole 2,4 DICHLOROBENZYL ALCOHOL Carbasalate Calcium Deutivacaftor Inclisiran Sodium Sodium 2-Hydroxylinoleate DISODIUM PHOSPHATE Ursodeoxycholic Acid Esomeprazole Siponimod Sodium Oxybate [99MTC]PSMA I&S Aminocaproic Acid Clarithromycin Quercetin Ecoo2 Flucloxacillin More therapies…

    Learn about Your Condition

    Hip arthroplasty Chondrosarcoma Head and neck cancer stage III Trisomy 21 Herpes virus infection Brain stem glioma Pulmonary resection Primary hyperthyroidism Biotinidase deficiency Peritoneal dialysis Mastocytosis Haemorrhage intracranial Angiosarcoma metastatic Obstructive pancreatitis Acute myeloid leukaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Malignant melanoma stage IV

  • Study of INCB099280 and Ipilimumab for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Malignant melanoma stage IV
    • Malignant melanoma
    • Colorectal adenocarcinoma
    Investigated Drugs:
    • Incb099280
    • Ipilimumab
    Norway Slovakia Sweden

  • Study on the Safety and Effects of ATL001 and Nivolumab for Adults with Metastatic or Recurrent Melanoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Desmoplastic melanoma
    • Malignant melanoma of eyelid
    • Malignant melanoma stage IV
    Investigated Drugs:
    • Atl001
    • Nivolumab
    Spain

  • Study on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma stage IV
    • Melanoma recurrent
    • Malignant melanoma stage III
    Investigated Drugs:
    • Autogene Cevumeran
    • Pembrolizumab
    Germany Spain

  • Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Binimetinib
    • Encorafenib
    • Pembrolizumab
    Belgium Bulgaria Czechia Finland Germany Greece +5

  • Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Central nervous system melanoma
    • Gastrointestinal melanoma
    • Malignant melanoma of eyelid
    Investigated Drugs:
    • Binimetinib
    • Encorafenib
    • Ipilimumab
    Germany Italy Poland Slovakia Spain

  • Study of INCB099280 for Patients with Advanced Solid Tumors Who Have Not Received Immunotherapy

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Incb099280
    Greece Hungary Romania
Previous Page
1 2

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!